Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
80,165,500
-
Total 13F shares
-
9,166,276
-
Share change
-
+191,757
-
Total reported value
-
$15,209,597
-
Put/Call ratio
-
55%
-
Price per share
-
$1.66
-
Number of holders
-
61
-
Value change
-
-$97,896
-
Number of buys
-
35
-
Number of sells
-
26
Institutional Holders of Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX) as of Q3 2023
As of 30 Sep 2023,
Protalix BioTherapeutics, Inc. - Common Stock, $0.001 par value per share (PLX) was held by
61 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
9,166,276 shares.
The largest 10 holders included
BlackRock Inc., STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, GSA CAPITAL PARTNERS LLP, NORTHERN TRUST CORP, VANGUARD GROUP INC, Nuveen Asset Management, LLC, MORGAN STANLEY, and BANK OF AMERICA CORP /DE/.
This page lists
61
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.